Scientific Advisory Board brings together world-class expertise in prostate cancer, hematologic malignancies, molecular imaging, radiochemistry and clinical developmentInternationally recognized advisers to support
The three abstracts strengthen the clinical foundation for Iomab-ACT's development as a targeted conditioning platform for cellular and gene therapies across cancer and nonmalignant diseasesPhase 1b/2 trial
Results report the safety of combining targeted alpha therapy with CLAG-M for patients with relapsed or refractory acute myeloid leukemiaLong-term follow-up evaluates bone marrow recovery and potential delayed kidney
Poster presentation to highlight preclinical efficacy of ATNM-400 across therapy-resistant breast cancer subtypesATNM-400 is a first-in-class targeted alpha therapy directed against HER3, a driver of tumor biology and
NEW YORK, Oct. 30, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced an inducement
First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapyHER3‑targeted alpha
HER3‑targeted PET imaging demonstrated tumor uptake and retention, supporting ATNM‑400's potential to deliver sustained alpha radiation to tumors over a timeframe consistent with Actinium‑225's 10-day
ATNM-400 demonstrated activity across EGFR-, KRAS- and ALK-driven lung cancer models, supporting mutation-agnostic development as monotherapy and in combination with established treatmentsIn colorectal cancer, adding
First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMAPreclinical presentation to feature ATNM-400
NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced inducement
Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic developmentColorectal cancer data
– Brings more than 20 years of oncology business development and commercial leadership, including senior roles across the radiopharmaceutical sector at Bayer, Clovis Oncology, Telix Pharmaceuticals and BWXT Medical–
Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC)Evaluation of
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that Sandesh Seth, Chairman and
